With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
According to the agreement, WuXi STA will become the preferred CDMO partner and provide Coherent Biopharma with integrated CMC services to accelerate its present and future drug candidates